Targeting the SYVN1-EGFR axis: a breakthrough strategy for TKI-resistant NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality.
• Molecular targeted therapies are crucial for NSCLC treatment, but acquired drug resistance presents a major challenge.
• Identifying novel therapeutic targets is essential for improving patient outcomes in NSCLC.

Purpose of the Study:

• To investigate synoviolin-1 (SYVN1) as a potential therapeutic target in NSCLC.
• To elucidate the mechanism by which SYVN1 influences epidermal growth factor receptor (EGFR) signaling in NSCLC.
• To evaluate the therapeutic potential of targeting the SYVN1-EGFR axis, particularly in overcoming drug resistance.

Main Methods:

• Verification of SYVN1 expression and its correlation with prognosis in NSCLC.
• Investigation of the interaction between SYVN1 and EGFR, including ubiquitination and degradation pathways.
• Assessment of the efficacy of SYVN1 inhibitor LS-102, alone and in combination with EGFR-TKI AZD9291, on NSCLC growth in vitro and in vivo.

Main Results:

• SYVN1 is highly expressed in NSCLC and associated with poor prognosis.
• SYVN1 directly interacts with EGFR, promoting its Lys63-linked ubiquitination, inhibiting proteasomal degradation, and increasing cell membrane levels.
• LS-102 inhibits SYVN1-driven proliferation, and the combination of LS-102 and AZD9291 effectively inhibits NSCLC growth and overcomes AZD9291 resistance.

Conclusions:

• The SYVN1-EGFR axis plays a critical role in NSCLC development and progression.
• SYVN1 promotes NSCLC growth by stabilizing EGFR and enhancing its signaling.
• Targeting the SYVN1-EGFR axis to destabilize EGFR represents a promising therapeutic strategy for TKI-resistant NSCLC.